Amgen To Shell Out $669M For Turkish Drugmaker

Law360, New York (April 25, 2012, 3:08 PM EDT) -- California biotech giant Amgen Inc. is grabbing a majority stake in Mustafa Nevzat Pharmaceuticals, a family-owned Turkish maker of cancer medicines and a vital portal to the Middle Eastern country's drug market, for about $669.2 million, the companies said Wednesday.

Approved by the boards of directors of both companies, the all-cash deal gives Amgen a 95.6 percent stake in MN Pharmaceuticals and boosts its presence in the fast-growing Turkish market that it has recently targeted as a key site for its international growth plans, Amgen said....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.